Cargando…

EGFR Inhibitor Erlotinib Delays Disease Progression but Does Not Extend Survival in the SOD1 Mouse Model of ALS

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes progressive paralysis due to motor neuron death. Several lines of published evidence suggested that inhibition of epidermal growth factor receptor (EGFR) signaling might protect neurons from degeneration. To test th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le Pichon, Claire E., Dominguez, Sara L., Solanoy, Hilda, Ngu, Hai, Lewin-Koh, Nicholas, Chen, Mark, Eastham-Anderson, Jeffrey, Watts, Ryan, Scearce-Levie, Kimberly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637182/ https://www.ncbi.nlm.nih.gov/pubmed/23638043 http://dx.doi.org/10.1371/journal.pone.0062342

Ejemplares similares

Cognitive Deficits, Changes in Synaptic Function, and Brain Pathology in a Mouse Model of Normal Aging
por: Weber, Martin, et al.
Publicado: (2015)

BACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats
por: Weber, Martin, et al.
Publicado: (2017)

Dual leucine zipper kinase is required for excitotoxicity-induced neuronal degeneration
por: Pozniak, Christine D., et al.
Publicado: (2013)

Characterization of Social Behaviors in caspase-3 deficient mice
por: Lo, Shih-Ching, et al.
Publicado: (2016)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Engineered G protein coupled receptors reveal independent regulation of internalization, desensitization and acute signaling
por: Scearce-Levie, Kimberly, et al.
Publicado: (2005)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

COL25A1 triggers and promotes Alzheimer’s disease-like pathology in vivo
por: Tong, Ying, et al.
Publicado: (2009)

Inducible EphA4 knockout causes motor deficits in young mice and is not protective in the SOD1(G93A) mouse model of ALS
por: Dominguez, Sara L., et al.
Publicado: (2020)

Antibody-mediated stabilization of NRG1 induces behavioral and electrophysiological alterations in adult mice
por: Dominguez, Sara L., et al.
Publicado: (2018)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
por: Sueangoen, Natthaporn, et al.
Publicado: (2020)

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
por: Park, Jin H., et al.
Publicado: (2012)

Advanced lung adenocarcinoma in an EGFR-positive patient treated with Erlotinib for 52 months
por: Gonçalves, Ivone, et al.
Publicado: (2013)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
por: Bartholomeusz, Chandra, et al.
Publicado: (2011)

Excellent response to erlotinib in breast carcinoma with rare EGFR mutation—a case report
por: Singh, Gunjesh Kumar, et al.
Publicado: (2020)

EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky
por: Larson, Kara L., et al.
Publicado: (2020)

Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib
por: Tomar, Shubham, et al.
Publicado: (2022)

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
por: Nakagawa, Kazuhiko, et al.
Publicado: (2022)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
por: Nakade, Junya, et al.
Publicado: (2014)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
por: Azuma, Koichi, et al.
Publicado: (2016)

Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib
por: Agbarya, Abed, et al.
Publicado: (2014)

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
por: Baty, Florent, et al.
Publicado: (2013)

Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
por: Schöttle, Jakob, et al.
Publicado: (2015)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
por: Dong, Jiang-Kai, et al.
Publicado: (2018)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR-mutated NSCLC cells in vitro and in vivo via STAT3/Bcl-2 signaling
por: Zhou, Xiaowen, et al.
Publicado: (2021)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib
por: ISHII, HIDENOBU, et al.
Publicado: (2014)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

Ezrin Enhances EGFR Signaling and Modulates Erlotinib Sensitivity in Non–Small Cell Lung Cancer Cells()
por: Saygideğer-Kont, Yasemin, et al.
Publicado: (2016)

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation
por: Niwa, Hideyuki, et al.
Publicado: (2018)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR‐mutant lung cancer
por: Kim, Dong Ha, et al.
Publicado: (2018)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rric3q746bf5ni2mblfbq2boi4